Repligen Corporation (RGEN) Income Statement

Year-over-year growth decelerated from a peak of 21.9% in 2025Q3 to 10.9% in 2026Q3, which appears to reflect normalization rather than deterioration given sequential revenue has increased for five consecutive quarters. Management's guidance raise and commentary on 13% organic growth imply that the company may be entering a more durable growth phase as commercial biologics manufacturing volumes recover. However, the moderation from ~20% to ~11% growth warrants monitoring, as it could indicate that the restocking tailwind is fading before organic demand fully replaces it.

The 2024Q4 collapse to 23.2% gross margin—driven by COGS of $128.7M on $167.5M of revenue—was clearly anomalous and likely tied to inventory normalization charges. Since then, gross margins have stabilized in the 50–53% range, consistent with the company's spec-in positioning in Protein A ligands and single-use consumables. This margin recovery appears sustainable for now, but the dependence on capacity utilization creates ongoing cyclicality risk; any future destocking cycle at large pharma or CDMO clients could compress margins quickly given the high fixed-cost component of manufacturing.

The 2026Q3 operating loss of -$29.5M is particularly concerning because gross profit of $111.0M minus R&D ($14.4M) and SG&A ($83.6M) yields only $13.0M, implying roughly $42.5M in additional unclassified charges—potentially restructuring, impairment, or acquisition-related costs. Even in profitable quarters like 2026Q2, the operating margin of just 5.8% versus gross margin of 53.1% suggests a bloated overhead structure relative to revenue. If these charges are one-time in nature, margins should recover, but the persistent SG&A creep over ten quarters suggests management may have over-expanded the cost base ahead of demand recovery.

The 2024Q4 write-down, characterized by $128.7M in COGS against $167.5M of revenue, likely represented the cumulative clearing of pandemic-era inventory build, and its passage enabled the gross margin recovery to 50%+ levels seen in every quarter since 2025Q1. This inflection has lasting structural significance because it reset the company's inventory carrying costs and allowed underlying gross margin economics to reassert themselves. The critical question for the next four quarters is whether operating margins can expand toward the historical 15–20% range, or whether the elevated SG&A base that accompanied the recovery represents a permanent step-up in the cost structure.